Dear Editor,
I have been following The Clinical Respiratory Journal and got insights for my research regarding respiratory and lung diseases. There are various research studies published for the diagnosis and treatment of lung diseases including cancer. Here, I have focused on lung cancer caused by tobacco and drugs, with the current state of health policy and possible improvements in it as a health advocate.
Smoking and drug addiction are the primary risk factors for lung cancer, leading to lung cancer having the biggest mortality rate of all cancers. Although it has decreased in men by 45% and women by 19% due to the US government’s smoking and drug prevention programs. CDC’s Office on Smoking and Health (OSH) started National Tobacco Control Program through interventions and policy-making strategies.
As a nurse and health advocate, I have analyzed the fact there are many shortcomings in tackling issues related to mental well-being and drug use. At first, it looks like a relief but causes serious organ damage and long-term addiction. Timely diagnosis of lung cancer and symptom identification can ease the situation and radiotherapy can be started to kill cancerous cells from the very start. Usually, they are not aware of the disease situation, the usual cough and breath shortness turn into blood vomiting and pain while breathing. Health advocates counsel people on how to recognize abnormal health and psychological situations. After the detection of the disease, an intervention plan including chemotherapy for cancer and rehabilitation for addiction is introduced (Jett et al., 2018).
There is a big treatment outcome difference in detecting cancer at 1st stage and last stage. American Lung Association works for preventive measures to reduce the risk of developing lung cancer through health advocacy programs. Discouraging the use of tobacco reduces the development of cancer. Low-dose CT scans for smokers with a high risk of lung cancer make early detection possible and reduce the death rate by 20%. The National Comprehensive Cancer Network (NCCN) has issued treatment guidelines that work for specific patent conditions because every lung cancer situation is different. It is important to participate in clinical trials to choose the best treatment strategy with the help of your health advocate (Bracken-Clarke et al., 2021). Although treatment coverage through insurance plans still needs to be improved. Lung screening coverage by the Lung association has gaps that require better management.
Development in the treatment of lung cancer and policies related to it is crucial. CT screening is more effective than radiotherapy but it has many obstacles in implementation such as high radiation exposure and cost. The study has recommended computer models for diagnosing lung cancer through machine learning and a web-based patient screening approach. This model framework solves the over-dose diagnosis problem and decreases error chances (Et. al., 2021).
Order this paper